Answers to frequently asked questions about the Avantect Pancreatic Cancer Test are listed below. If you do not find the information you are looking for, please feel free to contact us.
The Avantect Pancreatic Cancer Test is a next-generation, multi-analyte blood-based test designed to evaluate biologically relevant cancer-associated signals associated with pancreatic cancer. The test integrates epigenomic (5hmC), genomic features, and a glycan biomarker, interpreted together using optimized machine-learning models to generate a single, integrated result. The test is performed in ClearNote Health’s CLIA-certified and CAP-accredited laboratory
The Avantect Pancreatic Cancer Test is intended for individuals at elevated risk for pancreatic cancer, including:
The Avantect Pancreatic Cancer Test is not intended for average-risk population screening and should be used as part of physician-directed care alongside other clinical information.
Yes. ClearNote Health accepts specimens from Medicare patients.
The Avantect Pancreatic Cancer Test may be ordered by physicians or other authorized healthcare professionals.
The treating healthcare provider determines the testing protocol that is appropriate for each patient based on clinical judgment and individual risk factors.
The Avantect Pancreatic Cancer Test evaluates the presence or absence of a pancreatic cancer–associated signal by integrating multiple biological inputs, including epigenomic, genomic, and glycan-associated measurements.
In a case-control clinical validation study including pancreatic cancer patients (n=259) and non-cancer subjects (n=1,186), the Avantect Pancreatic Cancer Test demonstrated:
This performance is designed to support earlier detection in elevated-risk populations while maintaining high specificity to limit unnecessary downstream testing.
Traditional biomarkers such as CA19-9 or CEA have important limitations when used alone, particularly for early-stage pancreatic cancer detection. The Avantect Pancreatic Cancer Test does not rely on CA19-9 as a standalone marker. Instead, it integrates individualized glycan biomarker assessment with DNA-based epigenomic and genomic features to provide a more complete and personalized view of cancer-associated biology. This integrated, multi-analyte approach is a powerful tool that improves early detection performance while maintaining the specificity required to support confident clinical decision-making.
The Avantect Pancreatic Cancer Test is intended to complement imaging and clinical evaluation, not replace them.
The specific diagnostic pathway is determined by the treating healthcare provider.
ClearNote Health accepts all insurances and will bill payers according to their coverage policies for diagnostic testing. If a payer does not cover or reimburse for the Avantect Pancreatic Cancer Test, ClearNote Health offers financial assistance programs to support patient access.
ClearNote Health offers financial assistance for uninsured, and underinsured patients. Payment options include acceptance of insurance, HSAs, and FSAs, as well as prompt pay discounts, and flexible payment plans to help manage out-of-pocket costs. The ClearNote Health Customer Success Team assists patients and providers with insurance coverage questions, financial assistance eligibility, and individualized payment plan options. For assistance, please contact the ClearNote Health Customer Success Team at +1 833-258-7827.
Employers may contact the ClearNote Health Customer Success Team at +1 833-258-7827.
ClearNote Health bills insurance directly, if applicable. If patient responsibility exists, ClearNote Health invoices patients according to insurance coverage, financial assistance eligibility, or self-pay terms. Our Customer Success team can work with your patients before testing to provide a Good Faith Estimate based on the patient’s insurance plan and individual financial circumstances.
ClearNote Health bills insurance directly, if applicable. If patient responsibility exists, ClearNote Health invoices patients according to insurance coverage, subject to any financial assistance eligibility.
Providers establish an account through the Test Ordering section of the website. A ClearNote Health Customer Success Representative supports kit requests, ordering, and logistics.
We are accepting international orders through your local distributor. If we do not have a distributor identified in your area, please let our Customer Success Representative know your preferred laboratory for diagnostic services in your area. We will reach out to them to see if we can facilitate your order.
The Avantect Pancreatic Cancer Test requires two 10 mL Cell-Free DNA BCT® Streck tubes. These are provided as part of the Avantect Blood Collection Kit.
Patients do not need to fast prior to their blood draw.
ClearNote Health offers several phlebotomy options for Avantect blood collection. Please visit https://www.avantect.com/blood-draw/ to learn more.
Results are typically available within approximately 14 calendar days after sample receipt at the CLIA-certified and CAP-accredited laboratory.
A ClearNote Health Customer Success Representative will send the test result report through a secure, encrypted email to the ordering healthcare provider as soon as the report is ready.
Please contact our ClearNote Health Customer Success Department at
+1 833-258-7827 to cancel the order, and the Customer Success Representative will immediately process the cancellation request.
The test report summarizes the results generated from the Avantect Pancreatic Cancer Test, which is performed in ClearNote Health’s CLIA-certified and CAP-accredited laboratory. It provides background on what the results mean for the provider and the patient, recommended follow-up based on test results, and general information about the methods used for the test.
A Pancreatic Cancer Signal Not Detected result indicates that a cancer-associated signal was not identified at this time. This result does not exclude the presence of pancreatic cancer. Results should be interpreted in the context of the patient’s clinical risk profile, and continued surveillance or follow-up should be determined by the treating healthcare provider.
A Pancreatic Cancer Signal Detected result indicates that an abnormal signal associated with pancreatic cancer was identified. This result is not a diagnosis. In some cases, the signal may be associated with other pancreatic conditions (such as cysts or pancreatitis), or rarely, malignancy outside the pancreas. Further clinical evaluation is recommended.
The Avantect Pancreatic Cancer Test does not establish a diagnosis. Imaging and biopsy remain the standard of care for definitive diagnosis.
False-positive and false-negative results can occur. Discordant findings should be evaluated in the context of clinical judgment, and follow-up decisions are at the discretion of the treating healthcare provider.
Quantity Not Sufficient (QNS) indicates insufficient biological material to generate a confident result. A repeat blood draw may be appropriate.
The Avantect Pancreatic Cancer Test is designed to evaluate pancreatic cancer–associated signals. In rare cases, a detected signal may reflect other pancreatic conditions or malignancy outside the pancreas.
Please contact the ClearNote Health Customer Success Team at +1 833-258-7827.
The Avantect Pancreatic Cancer Test is an early detection test. The test does not establish a diagnosis of pancreatic cancer, and results should be considered in the context of other clinical criteria. Definitive diagnosis of pancreatic cancer usually requires a series of imaging scans, blood tests, and a biopsy. Not all pancreatic cancers will be detected. Some patients with pancreatic cancer may have a “Pancreatic Cancer Signal not detected” result. Some patients without pancreatic cancer may have a “Pancreatic Cancer Signal detected” result. False-negative and false-positive results are possible. A “Signal not detected” result does not guarantee that no pancreatic cancer is present. In some cases, no result is obtained. While this is very uncommon, it may be caused by shipping delays or when there is not enough cell-free DNA for the test in the patient’s blood. If this happens, we generally ask for a repeat blood sample for testing at no extra cost.
The test was developed in the ClearNote Health CLIA-certified (CLIA# 05D2249973) and CAP-accredited (CAP# 9219174) laboratory and has not been cleared or approved by the US Food and Drug Administration (FDA).